复星医药(02196.HK)拟设合资上海复健专注大健康领域基金的受托管理
格隆汇8月26日丨复星医药(02196.HK)公布,于2019年8月26日,公司与复星健控就拟设立合资公司上海复健股权投资基金管理有限公司订立投资协议。合资公司主要从事关于大健康领域基金的受托管理、投资管理及谘询服务。合资公司注册资本为人民币1000万元,其中,公司拟以现金出资人民币600万元,占合资公司60%的股权,复星健控拟以现金出资人民币400万元,占合资公司40%的股权。合资公司成立后,将成为公司的附属公司。
合资公司设立后,拟专注于大健康领域基金的受托管理,孵化并投资拥有领先技术的(其中包括)生物医药、医疗器械及诊断等技术领域的企业,强化大健康领域创新技术╱产品培育和布局。董事认为,有关投资协议的约定条款为一般商业条款,属公平合理,符合公司及其股东的整体利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.